Adva-27a, a novel podophyllotoxin derivative found to be effective against multidrug resistant human cancer cells

Abderrazzak Merzouki, Michael D. Buschmann, Myriam Jean, Rebecca S. Young, Si Liao, Susannah Gal, Zuomei Li, Steve N. Slilaty

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background/Aim: Multidrug resistance poses a serious challenge in cancer therapy. To address this problem, we designed and synthesized Adva-27a, a novel non-ester GEM-difluorinated C-glycoside derivative of podophyllotoxin. Materials and Methods: Adva-27a activity was evaluated in a variety of assays including inhibition of topoisomerase IIα, cytotoxic activity in drug-sensitive and drug-resistant cancer cell lines, metabolic stability in human liver microsomes and pharmacokinetic properties in rats. Results: Adva-27a exhibited dose-dependent human topoisomerase IIα inhibitory activity and dose-dependent growth inhibitory activity in several drug-sensitive and two multidrug-resistant cancer cell lines. In the multidrug-resistant cell lines, MCF-7/MDR (breast cancer) and H69AR (small-cell lung cancer), Adva-27a was significantly more potent than etoposide. The metabolic stability of Adva-27a in human liver microsomes and its pharmacokinetic properties in rats were better than those of etoposide. Conclusion: Our studies have identified Adva-27a as a novel topoisomerase II inhibitor with superior cytotoxic activity against multidrug-resistant human cancer cells and more desirable pharmacokinetic properties than etoposide.

Original languageEnglish (US)
Pages (from-to)4423-4432
Number of pages10
JournalAnticancer Research
Volume32
Issue number10
StatePublished - Oct 1 2012

Fingerprint

Podophyllotoxin
Etoposide
Type II DNA Topoisomerase
Pharmacokinetics
Liver Microsomes
Cell Line
Neoplasms
Pharmaceutical Preparations
Topoisomerase II Inhibitors
Small Cell Lung Carcinoma
Multiple Drug Resistance
Breast Neoplasms
Growth

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Merzouki, A., Buschmann, M. D., Jean, M., Young, R. S., Liao, S., Gal, S., ... Slilaty, S. N. (2012). Adva-27a, a novel podophyllotoxin derivative found to be effective against multidrug resistant human cancer cells. Anticancer Research, 32(10), 4423-4432.
Merzouki, Abderrazzak ; Buschmann, Michael D. ; Jean, Myriam ; Young, Rebecca S. ; Liao, Si ; Gal, Susannah ; Li, Zuomei ; Slilaty, Steve N. / Adva-27a, a novel podophyllotoxin derivative found to be effective against multidrug resistant human cancer cells. In: Anticancer Research. 2012 ; Vol. 32, No. 10. pp. 4423-4432.
@article{fabf4711bf274bfb88efe076e6823260,
title = "Adva-27a, a novel podophyllotoxin derivative found to be effective against multidrug resistant human cancer cells",
abstract = "Background/Aim: Multidrug resistance poses a serious challenge in cancer therapy. To address this problem, we designed and synthesized Adva-27a, a novel non-ester GEM-difluorinated C-glycoside derivative of podophyllotoxin. Materials and Methods: Adva-27a activity was evaluated in a variety of assays including inhibition of topoisomerase IIα, cytotoxic activity in drug-sensitive and drug-resistant cancer cell lines, metabolic stability in human liver microsomes and pharmacokinetic properties in rats. Results: Adva-27a exhibited dose-dependent human topoisomerase IIα inhibitory activity and dose-dependent growth inhibitory activity in several drug-sensitive and two multidrug-resistant cancer cell lines. In the multidrug-resistant cell lines, MCF-7/MDR (breast cancer) and H69AR (small-cell lung cancer), Adva-27a was significantly more potent than etoposide. The metabolic stability of Adva-27a in human liver microsomes and its pharmacokinetic properties in rats were better than those of etoposide. Conclusion: Our studies have identified Adva-27a as a novel topoisomerase II inhibitor with superior cytotoxic activity against multidrug-resistant human cancer cells and more desirable pharmacokinetic properties than etoposide.",
author = "Abderrazzak Merzouki and Buschmann, {Michael D.} and Myriam Jean and Young, {Rebecca S.} and Si Liao and Susannah Gal and Zuomei Li and Slilaty, {Steve N.}",
year = "2012",
month = "10",
day = "1",
language = "English (US)",
volume = "32",
pages = "4423--4432",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "10",

}

Merzouki, A, Buschmann, MD, Jean, M, Young, RS, Liao, S, Gal, S, Li, Z & Slilaty, SN 2012, 'Adva-27a, a novel podophyllotoxin derivative found to be effective against multidrug resistant human cancer cells', Anticancer Research, vol. 32, no. 10, pp. 4423-4432.

Adva-27a, a novel podophyllotoxin derivative found to be effective against multidrug resistant human cancer cells. / Merzouki, Abderrazzak; Buschmann, Michael D.; Jean, Myriam; Young, Rebecca S.; Liao, Si; Gal, Susannah; Li, Zuomei; Slilaty, Steve N.

In: Anticancer Research, Vol. 32, No. 10, 01.10.2012, p. 4423-4432.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Adva-27a, a novel podophyllotoxin derivative found to be effective against multidrug resistant human cancer cells

AU - Merzouki, Abderrazzak

AU - Buschmann, Michael D.

AU - Jean, Myriam

AU - Young, Rebecca S.

AU - Liao, Si

AU - Gal, Susannah

AU - Li, Zuomei

AU - Slilaty, Steve N.

PY - 2012/10/1

Y1 - 2012/10/1

N2 - Background/Aim: Multidrug resistance poses a serious challenge in cancer therapy. To address this problem, we designed and synthesized Adva-27a, a novel non-ester GEM-difluorinated C-glycoside derivative of podophyllotoxin. Materials and Methods: Adva-27a activity was evaluated in a variety of assays including inhibition of topoisomerase IIα, cytotoxic activity in drug-sensitive and drug-resistant cancer cell lines, metabolic stability in human liver microsomes and pharmacokinetic properties in rats. Results: Adva-27a exhibited dose-dependent human topoisomerase IIα inhibitory activity and dose-dependent growth inhibitory activity in several drug-sensitive and two multidrug-resistant cancer cell lines. In the multidrug-resistant cell lines, MCF-7/MDR (breast cancer) and H69AR (small-cell lung cancer), Adva-27a was significantly more potent than etoposide. The metabolic stability of Adva-27a in human liver microsomes and its pharmacokinetic properties in rats were better than those of etoposide. Conclusion: Our studies have identified Adva-27a as a novel topoisomerase II inhibitor with superior cytotoxic activity against multidrug-resistant human cancer cells and more desirable pharmacokinetic properties than etoposide.

AB - Background/Aim: Multidrug resistance poses a serious challenge in cancer therapy. To address this problem, we designed and synthesized Adva-27a, a novel non-ester GEM-difluorinated C-glycoside derivative of podophyllotoxin. Materials and Methods: Adva-27a activity was evaluated in a variety of assays including inhibition of topoisomerase IIα, cytotoxic activity in drug-sensitive and drug-resistant cancer cell lines, metabolic stability in human liver microsomes and pharmacokinetic properties in rats. Results: Adva-27a exhibited dose-dependent human topoisomerase IIα inhibitory activity and dose-dependent growth inhibitory activity in several drug-sensitive and two multidrug-resistant cancer cell lines. In the multidrug-resistant cell lines, MCF-7/MDR (breast cancer) and H69AR (small-cell lung cancer), Adva-27a was significantly more potent than etoposide. The metabolic stability of Adva-27a in human liver microsomes and its pharmacokinetic properties in rats were better than those of etoposide. Conclusion: Our studies have identified Adva-27a as a novel topoisomerase II inhibitor with superior cytotoxic activity against multidrug-resistant human cancer cells and more desirable pharmacokinetic properties than etoposide.

UR - http://www.scopus.com/inward/record.url?scp=84867825159&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867825159&partnerID=8YFLogxK

M3 - Article

C2 - 23060568

AN - SCOPUS:84867825159

VL - 32

SP - 4423

EP - 4432

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 10

ER -